Haplotype analysis of GSK-3β gene polymorphisms in bipolar disorder lithium responders and nonresponders

Clin Neuropharmacol. 2014 Jul-Aug;37(4):108-10. doi: 10.1097/WNF.0000000000000039.

Abstract

The GSK-3β gene, GSK3B, codes for an enzyme that is a target for the action of mood stabilizers, lithium and possibly valproic acid.In this study, the relationship between haplotypes consisting of single nucleotide polymorphisms (SNPs) of GSK3B -50T/C and -1727A/T and the effect of lithium was studied among Japanese bipolar disorder lithium nonresponders and responders.The distributions of the GSK3B haplotypes (-50T/C and -1727A/T) showed a trend for significant difference between the lithium nonresponders and responders (global P=0.07074). Haplotype 1 (T-A) was associated with a higher lithium response (haplotype-specific P=0.03477), whereas haplotype 2 (C-A) was associated with a lower lithium response (haplotype-specific P=0.03443).The pairwise D' and r values between the 2 SNPs in this study were 1.0 and 0.097, respectively. The 2 SNPs showed weak linkage disequilibrium with each other.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antimanic Agents / therapeutic use*
  • Bipolar Disorder / drug therapy*
  • Bipolar Disorder / genetics*
  • Female
  • Genetic Association Studies
  • Glycogen Synthase Kinase 3 / genetics*
  • Glycogen Synthase Kinase 3 beta
  • Haplotypes
  • Humans
  • Japan
  • Lithium Chloride / therapeutic use*
  • Male
  • Pharmacogenetics
  • Polymorphism, Single Nucleotide / genetics*

Substances

  • Antimanic Agents
  • GSK3B protein, human
  • Glycogen Synthase Kinase 3 beta
  • Glycogen Synthase Kinase 3
  • Lithium Chloride